THERAPY DOSSIER · th-7826bc5c2f57

Protein C concentrate

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01127529 ↗Phase not recordedcompleted

Ceprotin (Protein C Concentrate, Human) treatment registry in protein C deficiency

Protein C Deficiency

Enrolment: 43 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21907691 ↗2011Reported benefit

Protein C concentrate controls leukocyte recruitment during inflammation and improves survival during endotoxemia after efficient in vivo activation.

MouseEndotoxin/LPSC57BLIntravenous100 U/kgDuring acute inflammation

Model: LPS endotoxemia and TNF-alpha/trauma-induced acute inflammation

Protein C concentrate inhibited leukocyte recruitment and improved survival during murine endotoxemia (75% vs 25%).

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…